Sinopharm Accord's net profit attributable to shareholders for the first three quarters was 957 million yuan, a year-on-year decrease of 10.18%

According to the Zhitong Finance APP, Sinopharm Accord (000028.SZ) disclosed its performance report for the first three quarters of 2025. The company achieved an operating income of 55.124 billion yuan, a year-on-year decrease of 2.38%; the net profit attributable to shareholders of the listed company was 0.957 billion yuan, a year-on-year decrease of 10.18%, and the corresponding basic earnings per share decreased by 9.95% year-on-year.

From January to September 2025, the distribution segment achieved an operating income of 40.594 billion yuan, a year-on-year decrease of 0.59%; the net profit was 0.723 billion yuan, a year-on-year decrease of 7.32%. In the third quarter, the distribution business continued to face policy and market competition pressures, but the company stabilized and rebounded its distribution revenue through continuous optimization of its business structure. At the same time, due to the longer collection cycle of some downstream customers, the provision for credit impairment losses increased year-on-year, leading to a decline in profits. However, the company insisted on business adjustment and cost control, resulting in a narrowing of the profit decline. The retail segment achieved an operating income of 15.226 billion yuan, a year-on-year decrease of 7.14%; the net profit was 0.013 billion yuan, a year-on-year increase of 133.91%